USP18 and cancer: It has been reported that engineered gain of USP18 decreases cancer growth by destabilizing growth-regulatory proteins (Mustachio et al., 2018), which suggests that USP18 may alter transcribed mRNA catabolic process and translational initiation to facilitate the pathogenesis of SLE.